Caristo Diagnostics

Company profile

About Caristo Diagnostics

Caristo Diagnostics is a global leader in cardiovascular disease diagnostics and risk prediction, spun out from the University of Oxford. The company has developed CaRi-Heart®, a breakthrough AI technology that analyzes routine coronary computed tomography angiography (CCTA) scans to visualize and quantify coronary inflammation—the otherwise invisible disease mechanism responsible for many fatal heart attacks and strokes. The technology applies advanced AI algorithms to standard cardiac CT imaging to detect inflammation that traditional imaging methods cannot see, transforming CCTA from a diagnostic tool into a powerful prevention platform. Caristo's flagship product includes the FAI-Score™ for inflammation measurement, CaRi-Plaque™ Analysis for plaque assessment, and an Individualised Risk Score that outperforms traditional risk prediction models. The technology has been validated in landmark clinical studies including the ORFAN registry, the world's largest coronary CT registry with 40,000+ patients, published in The Lancet. Results demonstrate that CaRi-Heart can predict fatal and non-fatal cardiac events at least 10 years in advance, even in patients without obstructive coronary artery disease. The company serves clinicians, health systems, pharmaceutical companies conducting clinical trials, and patients seeking advanced cardiac risk assessment. CaRi-Heart technology is currently in clinical use across the UK, European Union, and Australia, with investigational use status in the United States.

Company description · Caristo Diagnostics official website